Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association

Authors, Journal, Affiliations, Type, DOI

• Tiffany M. Powell-Wiley (Chair), Paul Poirier (Vice Chair), Lora E. Burke, Jean-Pierre Després, Penny Gordon-Larsen, Carl J. Lavie, Scott A. Lear, Chiadi E. Ndumele, Ian J. Neeland, Prashanthan Sanders, Marie-Pierre St-Onge; on behalf of the American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council
• Circulation 2021;143:e984–e1010
• Multi-institutional (NIH, Université Laval, Ochsner Medical Center, Johns Hopkins, University of Adelaide, Columbia University, et al.)
• AHA Scientific Statement
• DOI: 10.1161/CIR.0000000000000973

Overview

This AHA scientific statement provides a comprehensive update on the relationship between obesity and cardiovascular disease, covering visceral adiposity biology, CAD pathophysiology and diagnosis, heart failure, and arrhythmias (SCD and AF). The statement highlights that BMI alone is insufficient to capture CVD risk — visceral and ectopic fat (especially epicardial adipose tissue) are independent risk markers. Obesity is the most common nonischaemic cause of SCD and accounts for approximately one-fifth of all AF cases. Medical weight loss does not clearly reduce CAD rates, but bariatric surgery does; and weight loss ≥10% confers a nearly 6-fold higher likelihood of freedom from AF at 5 years.

Keywords

AHA Scientific Statements, atrial fibrillation, cardiovascular diseases, coronary artery disease, death (sudden), heart, heart failure, obesity

Key Takeaways

Epidemiology

• Global obesity: 603.7 million adults with obesity in 2015; prevalence doubled in 73 countries between 1980 and 2015; 39–49% of the world population has overweight or obesity.
• US crude obesity prevalence: 39.8% in 2015–2016 (up from 37.9% in 2013–2014); class 3 obesity (BMI ≥40) at 7.7%.
• High BMI accounted for 4.0 million deaths globally in 2015 — two-thirds from cardiovascular disease.
• Structural racism, weight stigmatization, and socioeconomic inequality contribute to racial/ethnic disparities in obesity and CVD outcomes in the US.

Visceral Adiposity, Liver Fat, and CVD Risk

• Waist circumference (WC) is an indicator of abdominal fat independent of BMI; high WC even at normal BMI unmasks elevated CVD risk ("normal-weight obesity").
• Visceral adipose tissue (VAT): at any BMI level there is 2- to 3-fold variation in VAT; excess VAT (vs metabolically healthy obesity) represents highest CVD risk subgroup.
• Metabolically healthy obesity may be a transient phenotype — the majority progress to metabolically unhealthy obesity over time, with variation by race/ethnicity and sex.
• Nonalcoholic fatty liver disease is the most common clinical manifestation of liver fat accumulation, itself associated with the same CVD risk factor alterations as visceral obesity; Mendelian randomisation studies do not show liver fat causally linked to CVD independently.
• Imaging (CT/MRI) quantifies VAT, subcutaneous fat, and ectopic fat depots; WC and WHR are the most practical clinical proxies.

Ectopic Fat Depots and CVD Risk

• Pericardial fat: Total fat within pericardial sac, associated with traditional CVD risk factors and atherogenic lipoproteins; associated with all-cause CVD, atherosclerotic CVD, and HF in MESA; adds risk discrimination beyond clinical parameters and CAC scores. Not independently predictive of incident CVD beyond traditional risk factors in all studies.
• Epicardial adipose tissue (EAT): Visceral fat between outer myocardium wall and visceral pericardium; originates from embryonic brown adipose tissue; releases cytokines and chemokines; associated with arterial stiffness, insulin resistance, dyslipidemia, blood pressure, and sleep apnoea severity.
• EAT may be mobilized by CPAP therapy, though short-term CPAP (8–12 weeks) does not appear to affect VAT.

Impact of Lifestyle Interventions on Ectopic/Pericardial Fat

• Aerobic exercise (3–5 sessions/week for 12–52 weeks) reduces VAT by ~6.1% even in the absence of weight loss (meta-analysis).
• 150 min/week physical activity may be sufficient to reduce VAT; additional activity does not confer further reductions in some studies.
• Caloric restriction is also effective; combined lifestyle interventions (Diabetes Prevention Program, Look AHEAD) produce greater reductions.
• Exercise also reduces hepatic fat and epicardial/pericardial fat.

Pathophysiology of CAD in Obesity

• Atherosclerosis: Obesity accelerates atherosclerosis through insulin resistance, inflammation, and endothelial dysfunction. Visceral adiposity → systemic/vascular inflammation → LDL oxidation → atherogenesis. Carotid IMT (early atherosclerosis marker) is elevated in obesity, particularly chronic obesity from youth.
• Incident CAD: Every 5-unit BMI increment in the overweight/obese range is associated with elevated CAD risk; at each BMI level, higher WC/WHR confers additional CAD risk. Cumulative BMI-years and WC-years are stronger predictors than single measurements.
• Mediation controversy: Some large prospective analyses show the obesity–CAD link is largely mediated by hypertension, dyslipidemia, and diabetes; others show residual CAD risk beyond traditional risk factors. A meta-analysis (1.8 million individuals) estimated ~50% of the association is explained by traditional risk factors.
• Microvascular disease: Obesity is linked to coronary microvascular disease (via endothelial dysfunction and small-vessel remodeling); coronary microvascular disease provides independent prognostic information in obesity; bariatric surgery improves microvascular function.

Diagnosis of CAD in Obesity

• ECG: Multiple ECG changes with obesity (↑HR, ↑QRS, ↑QTc, left axis deviation, false-positive inferior MI criteria). LVH is underdiagnosed by standard criteria in severe obesity; Cornell score (R in AVL + S in V3: >35 mm men, >25 mm women) has best sensitivity (49%) and specificity (93%).
• Treadmill stress test: Limited by ECG abnormalities, reduced aerobic capacity (pulmonary dysfunction, LVDD, orthopedic); patients often fail to reach 85% maximal HR. Standard Bruce/modified Ramp protocols still achieve valid results in most.
• SPECT: Attenuation artifacts common; technetium sestamibi preferred; generally avoided at BMI >35 kg/m² — PET preferred.
• PET rubidium: 91% sensitivity, 89% specificity; less radiation; superior image quality with attenuation correction; quantifies absolute coronary blood flow; nuclear imaging technique of choice for obesity.
• Stress echocardiography: Valid technique with no weight limits; contrast injection improves sensitivity (82% vs 70%) and specificity (78% vs 67%) in obesity; highly operator-dependent; excellent 1-year outcomes with normal stress echo.
• Stress cardiac MRI: Least affected by obesity with PET; newer 70-cm bore MRIs accommodate patients better; 89% diagnostic image quality at mean BMI 34 kg/m²; annual MACE rate 0.3% with no inducible ischaemia.
• CT calcium scan: Obesity associated with higher CAC and more rapid CAC progression; equipment table limits and gantry diameter are practical constraints.
• CT coronary angiography: Sensitivity and negative predictive value remain high even in obesity despite image quality degradation from background noise and low vessel opacification.
• Invasive coronary angiography: Technical challenges (suboptimal visualization, access difficulty); radial access preferred — 3× lower complication rate than femoral in severe obesity; fluoroscopy produces higher radiation for both patient and staff.

Clinical Management and Treatment of CAD in Obesity

• Obesity paradox in CVD: Patients with overweight or class 1 obesity who develop symptomatic CVD have better short-term outcomes (≤10 years) than normal-weight patients. Proposed mechanisms: lead time bias (earlier CVD diagnosis), cardiorespiratory fitness differences, reserve against cardiac cachexia. The paradox wanes with class 3 obesity.
• Medical weight loss and CAD: Lifestyle modification improves metabolic syndrome, inflammation, and endothelial dysfunction, but clinical trials have not demonstrated a clear reduction in CAD rates. Post hoc analyses of Look AHEAD show ≥10% weight loss significantly reduces CV events.
• Bariatric surgery and CAD: Prospective studies (Swedish Obese Subjects — SOS study) show significantly lower fatal and nonfatal CV events vs non-surgical controls; retrospective study (n=20,235) shows lower CAD incidence. No RCT yet.
• PCI in obesity: Short-term: obesity paradox documented (BMI >25 independently predicts greater survival at 5 years in multiple registries). Long-term: U-shaped relationship with lowest MACE near BMI 30; obesity paradox wanes at class 3 obesity (5- and 10-year mortality higher than normal BMI in APPROACH registry).
• Antiplatelet therapy in obesity: Higher platelet reactivity in obesity; high on-aspirin platelet reactivity more prevalent; ticagrelor is not affected by BMI (unlike aspirin/clopidogrel/prasugrel); clinical outcomes data are insufficient to recommend dose adjustments.
• CABG in obesity: Higher postoperative renal failure, respiratory failure, arrhythmias (especially AF), sternal wound infection; bilateral IMA not superior to single IMA and may increase infection risk. Conflicting data on in-hospital and long-term mortality — meta-analyses suggest protective effect for overweight/mild obesity; class 3 obesity associated with higher in-hospital mortality in some registries.

Pathophysiology of HF and Arrhythmias in Obesity

• Cardiac structural effects: Excess adiposity → higher blood volume, cardiac output, higher BP (RAAS + sympathetic activation) → concentric LVH → LVDD → HFpEF. Obesity also causes myocardial fat accumulation and fibrosis.
• Obesity-HFpEF phenotype: Compared with non-obese HFpEF, patients with obesity + HFpEF have greater concentric LV remodeling, RV dilatation and dysfunction, pericardial restraint, ventricular interdependence (greater epicardial fat thickness/volume), and significantly lower exercise capacity — a distinct pathophysiological phenotype.

Obesity and HF

• HF incidence increases by 5% per BMI unit (men) and 7% per BMI unit (women) after adjustment for other risk factors (Framingham).
• HFpEF is more strongly associated with obesity than HFrEF: overweight → 38% higher HFpEF risk; class 1 obesity → 56% higher HFpEF risk, independently of other CVD risk factors (Pandey et al., pooled analysis of 3 longitudinal studies).
• Obesity paradox in HF: overweight/class 1 obesity have better outcomes than normal weight for both HFrEF and HFpEF (though less consistent for HFpEF).
• Patients with obesity have lower BNP than normal-weight patients — including in HF. Weight loss after bariatric surgery increases NT-proBNP levels concomitantly with improved LVDD.
• Low fitness explains ~50% of HF risk attributable to BMI.

Obesity and SCD

• Every 5-unit BMI increment confers a 16% higher risk of SCD.
• Obesity is the most common nonischaemic cause of SCD.
• Mechanisms: LVH, QT prolongation, premature ventricular complexes, autonomic imbalance, QRS fragmentation (surrogate for heterogeneous conduction), myocardial fibrosis.
• Epicardial adipose tissue: associated with premature ventricular contractions, VT/VF, SCD mortality; infiltrates atrial myocardium → fibrosis → reentrant circuits for lethal arrhythmias.
• Higher thoracic impedance with obesity → impaired defibrillation success; body habitus may compromise chest compression and airway protection in cardiac arrest.

Obesity and Atrial Fibrillation

• Obesity may account for ~1/5 of AF cases and 60% of recently documented population increases.
• Every 5-unit BMI increment confers a 29% greater risk of incident AF; 10% increase in postoperative AF; 13% increase in post-ablation AF.
• BMI 30–34.9 kg/m²: 54% increased likelihood of progression from paroxysmal to permanent AF. Class 2 obesity (BMI 35–39.9): 87% increase.
• Mechanisms: structural (LA remodeling, fibrosis) and electrical remodeling via epicardial fat infiltrating atrial myocardium → conduction block, voltage abnormalities, AF vulnerability.
• Epicardial fat association with AF is stronger than with measures of overall or abdominal obesity; proximity to atrial myocardium enables paracrine signaling.

Treatment of HF and Arrhythmias in Obesity

• Lifestyle in HF: Physical activity and improved fitness are highly encouraged; no strong evidence that weight reduction per se improves major HF outcomes; weight loss improves candidacy for LVAD/transplantation.
• Medications for weight loss in HF: GLP-1 agonists (liraglutide) and SGLT2 inhibitors show promise for weight loss and HF hospitalization/CV death reduction; dapagliflozin reduced risk of worsening HF or CV death in overweight/obese HFrEF (regardless of diabetes).
• Obesity and AF management — weight loss as the 4th pillar: A RCT (n=150) of intensive weight loss + cardiometabolic risk factor management vs standard care: greater reduction in AF burden and severity at 15 months. Long-term follow-up (5 years): individuals achieving ≥10% weight loss had a nearly 6-fold higher likelihood of freedom from AF. Weight loss reduces propensity for AF disease progression.

Limitations of the Document

• Predominantly reviews observational and retrospective data; few randomized controlled trials on surgical/medical weight loss and CVD outcomes.
• The obesity paradox may reflect lead time bias, confounding by fitness, and selection effects — causal mechanism unproven.
• No randomized controlled trial exists for bariatric surgery vs medical therapy and major adverse cardiovascular events (MACE).
• Racial/ethnic diversity in clinical trial populations remains inadequate; findings may not be generalizable across all populations.
• Medical weight loss interventions used in trials achieved only modest weight loss (5–10 kg), insufficient to separate from the surgery data.

Key Concepts Mentioned

• concepts/Visceral-Adiposity — central CVD risk marker beyond BMI; VAT, epicardial and pericardial fat
• concepts/Obesity-Paradox — improved short-term CVD outcomes in overweight/mild obesity
• concepts/HFpEF — obesity as dominant HFpEF risk factor; distinct obesity-HFpEF phenotype
• concepts/Sudden-Cardiac-Death — obesity as most common nonischaemic SCD cause
• concepts/LVOTO — LV diastolic dysfunction in obesity

Key Entities Mentioned

• entities/Obesity — the primary subject of this statement
• entities/Atrial-Fibrillation — obesity-AF epidemiology, epicardial fat mechanism, weight-loss treatment
• entities/Heart-Failure — obesity as HF risk factor, obesity paradox in HF
• entities/Coronary-Artery-Disease — obesity-CAD pathophysiology, diagnosis, obesity paradox in PCI/CABG

Wiki Pages Updated

• Created: wiki/entities/Obesity.md
• Created: wiki/concepts/Obesity-Paradox.md
• Created: wiki/concepts/Visceral-Adiposity.md
• Updated: wiki/entities/Atrial-Fibrillation.md (added Obesity as AF Risk Factor section)
• Updated: wiki/entities/Heart-Failure.md (added Obesity and Heart Failure section)
• Updated: wiki/concepts/HFpEF.md (added obesity-HFpEF phenotype to Epidemiology and Pathophysiology)
• Updated: wiki/wikiindex.md
• Updated: wiki/sourceindex.md